Expanded Access Policy

  • ProKidney is developing rilparencel for patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM).
  • ProKidney is not currently accepting requests for Expanded Access. Consistent with our commitment to bring innovative, safe, and effective therapies to patients, we are currently focused on our clinical development program. This will allow us to pursue regulatory approvals and potentially make our therapies available to future patients as quickly and safely as possible.
  • ProKidney reviews its policies from time to time to ensure conformity with applicable laws and regulations. We reserve the right to revise this policy at any time.
REGEN-007